THU437 - Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment.

MLA

Janjua, Naveed, et al. “THU437 - Real-World Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Treatment.” Journal of Hepatology, vol. 73, Aug. 2020, pp. S356–57. EBSCOhost, https://doi.org/10.1016/S0168-8278(20)31209-5.

APA

Janjua, N., Wilton, J., Cook, D., Wong, S., Butt, Z., Bartlett, S., Pearce, D. M., Ramji, A., Yoshida, E., Yu, A., Alvarez, M., Binka, M., & Krajden, M. (2020). THU437 - Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment. Journal of Hepatology, 73, S356–S357. https://doi.org/10.1016/S0168-8278(20)31209-5

Chicago

Janjua, Naveed, James Wilton, Darrel Cook, Stanley Wong, Zahid Butt, Sofia Bartlett, Dr. Margo Pearce, et al. 2020. “THU437 - Real-World Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Treatment.” Journal of Hepatology 73 (August): S356–57. doi:10.1016/S0168-8278(20)31209-5.